Refine by
Immune Evasion Suppliers & Manufacturers
7 companies found
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the ...
based inWatertown, MASSACHUSETTS (USA)
Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for effective delivery of gene therapies. We are inventing new ways to design ...
Our CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR ...
based inPaddington, AUSTRALIA
Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain. Pain and inflammation are responsible for a series of events leading to ...
Progenza is a cryopreserved multi-synergistic therapy targeting pain and inflammation. Regeneus has patented techniques and high-quality testing to ensure the production of millions of Progenza™ doses from a single donor ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer ...